Key factors
sym | COCP |
exch | US |
MCap | 14.65M |
Beta | 1.339 |
EPS | -1.97 |
Div date | 0000-00-00 |
Yesterday
sym | COCP |
exch | US |
close | 1.43 |
50 Day MA | 1.507 |
200 Day MA | 1.942 |
52 Week High | 3.285 |
52 Week Low | 1.325 |
Target Price | 8.0 |
Market Cap Mln | 14.65 |
Share statistics
Shares Outstanding | 10.17M |
Shares Float | 7113.11K |
Percent Institutions | 6.72 |
PercentInsiders | 30.02 |
SharesShort | 4965.0 |
Short Ratio | 0.29 |
Shares Short Prior Month | 3712.0 |
Short Percent | 0.050 |
Income
Revenue TTM | 510.0K |
Revenue Per Share TTM | 0.006 |
Quarterly Revenue Growth YOY | 26.89 |
Gross Profit TTM | -8794.0K |
EBITDA | -19.7M |
Diluted Eps TTM | -1.97 |
earning
EPS Estimate Current Quarter | -0.6 |
EPS Estimate Current Year | -2.18 |
EPS Estimate Next Quarter | -0.65 |
EPS Estimate Next Year | -1.47 |
Earnings Share | -1.97 |
Dividend
Dividend Date | 2018-01-24 |
Last Split Date | 2022-10-11 |
Last Split Factor | 1:12 |
business
Enterprise Value Ebitda | 0.412 |
Enterprise Value Revenue | 17.89 |
Book Value /share | 3.017 |
Price Book MRQ | 0.597 |
Price Sales TTM | 92.45 |
ReturnOnAssetsTTM | -0.31 |
ReturnOnEquityTTM | -0.48 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US19188J3005 |
CIK | 1412486 |
Code | COCP |
CUSIP | 09072E103 |
Employer Id Number | 35-2528215 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-12 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 12.0 |
IPODate | 2011-05-19 |
International Domestic | Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Cocrystal Pharma Inc |
Address | 19805 North Creek Parkway, Bothell, WA, United States, 98011 |
Country Name | USA |
Phone | 305 425 1780 |
Web URL | https://www.cocrystalpharma.com |
Logo URL | /img/logos/US/COCP.png |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.